Clinical Evidence Requirements by Risk Class in Colombia

1. Key takeaways

Colombia has no clinical evaluation guideline standing outside Decreto 4725 de 2005; clinical evidence is not a separately listed submission module but is reviewed as a component of the technical documentation under Article 18. This determines that its volume is decided by the risk classification: Class I and IIa devices follow the automatic registration route of Art. 17, whose official review timeline is only 2 working days, while Class IIb and III devices follow the standard registration route of Art. 16 with a review timeline of 90 working days. When the intensity of review differs by dozens of times, the volume of evidence must differ too.

The three-tier allocation framework proposed by GRZAN, with Class IIa relying mainly on literature, Class IIb requiring the product’s own performance data, and Class III requiring a complete clinical evidence chain, is a practical estimate rather than a statutory requirement. Its value is to avoid overinvestment on low-risk products while preventing high-risk products from being returned wholesale because their evidence takes the wrong form.

2. Legal basis

3. Expert insights

#### 1. Two working days does not mean clinical evidence is exempt; it means the certificate comes first and the check comes after

The official review timeline for automatic registration is 2 working days, a number routinely misread as meaning that low-risk products need no clinical evidence at all. The actual institutional design sits in Article 57 of Ley 962 de 2005: INVIMA must perform a post-grant control within 15 days of issuing the certificate. The evidence is not unchecked; the check is moved to after the certificate. GRZAN’s conclusion from this is that clinical evidence for automatic registration products cannot be skipped, only deferred and held ready for inspection, and it must be producible now. A product whose evidence is assembled only after the post-grant control notice arrives has already lost the race that the 15-day window sets.

#### 2. Classification determines the form of evidence, not whether evidence exists

The four classification logics of Art. 6 and the 18 classification rules of Art. 7 place the product into the four-tier framework of Class I, IIa, IIb and III. GRZAN’s three-tier allocation logic runs as follows: Class IIa relies on literature on equivalent devices and marketing history, with the argument centered on equivalence; Class IIb must add the product’s own performance and safety data, with literature serving only as background; Class III requires a complete evidence chain including clinical data itself, statistical methodology and adverse event analysis. The value of this line is that it converts the binary question of whether to run a clinical study into the operational question of what form the evidence must take.

#### 3. Wrong evidence form is more fatal than insufficient evidence volume

Within the 90 working days of standard registration, the most common challenge a Class III applicant faces is not that the data are too few but that the data do not answer the question: large bodies of literature are filed without any analysis targeted at the indication under application, or performance verification is done without any link established to clinical outcomes. GRZAN’s practice is to write a clinical evaluation conclusion summary first, aligning three columns, the indication under application, the risk points, and the evidence that answers each, and only then decide what to add. Filling gaps identified this way costs a fraction of filling gaps identified by a reviewer’s deficiency letter.

#### 4. Evidence maintenance across the 10-year validity of the certificate

The medical device registration certificate is uniformly valid for 10 years, and the renewal window opens at least 3 months before expiry. Clinical evidence is not a one-time deliverable: vigilance data, literature updates and safety signals from similar products all enter the scope of renewal and change procedures. GRZAN recommends establishing an evidence update mechanism at first submission, so that renewal never becomes the moment one discovers that newer literature has overturned the original benefit-risk conclusion. A mechanism built early costs little; a conclusion rebuilt under renewal pressure costs a renewal.

4. Practical recommendations

1. Have GRZAN lock the risk class under Art. 6 and Art. 7 first, then fix the evidence form under the three-tier framework, without assuming a uniform template in advance.
2. Have the foreign manufacturer prepare the evidence package by risk class: literature and marketing history for Class IIa, the product’s own performance data for Class IIb, and a complete clinical evidence chain for Class III.
3. Have the medical writer produce the three-column alignment table of indication, risk points and corresponding evidence as the opening page of the file.
4. Have the registration specialist maintain the ready-for-inspection materials for the automatic registration route in parallel, anticipating the post-grant control within 15 days of issuance.
5. Have GRZAN operate an annual review mechanism for literature and vigilance signals covering the 10-year validity of the certificate.
6. Have the applicant start renewal at least 3 months before expiry, filing the updated evidence conclusions together with the renewal application.

5. Verification checklist

• □ The risk class is locked under the 18 rules of Art. 7, with the route set as Art. 16 or Art. 17
• □ The evidence form matches the risk class: literature for IIa, own data for IIb, complete chain for III
• □ The three-column alignment table of indication, risk points and evidence has been produced
• □ Automatic registration products have ready-for-inspection materials for the post-grant control within 15 days of issuance
• □ Clinical evidence documents carry an official Spanish translation
• □ The evidence update and literature review mechanism covers the 10-year validity period
• □ Renewal is scheduled within the window of at least 3 months before expiry

Regulatory information verified as of October 29, 2026

All conclusions for external use are based on the current regulatory texts published by the competent authorities and are verified item by item before delivery.

GRZAN supports manufacturers entering the Colombian market with registration dossiers and conformity documentation, including clinical evidence strategy by risk class, evidence chain assembly, literature review mechanisms and renewal support for INVIMA submissions. For inquiries, contact info@grzanglobal.com.